Log In
Print this Print this

AdCh63-MVA malaria vaccine

Also known as: formerly PlaMaVax

  Manage Alerts
Collapse Summary General Information
Company GlaxoSmithKline plc
DescriptionHeterologous prime-boost regimen with vectors encoding for ME-TRAP, a chimeric malaria antigen composed of the liver-stage TRAP antigen fused to a polyepitope string including T and B cell epitopes from different stages of the parasite life cycle
Molecular Target Not applicable
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine
Latest Stage of DevelopmentPhase II
Standard IndicationMalaria
Indication DetailsVaccinate against malaria
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today